Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

'Humanized' Mice Speak Volumes
Mice carrying a "humanized version" of a gene believed to influence speech and language may not actually talk, but they nonetheless do have a lot to say about our evolutionary past, according to a report in the May 29th issue of the journal Cell, a Cell Press publication.
generic viagra online
Overall Cardiovascular Safety Of Rosiglitazone Confirmed In 5 1/2-Year Study
Results of the long-awaited Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) study were presented here in a symposium at the American Diabetes Association"s 69th Scientific Sessions. The results are being simultaneously published online in The Lancet.
News of the day
NICE Issues Positive Final Appraisal Determination Recommending The Use Of Basilea's Toctino
Basilea Pharmaceutica Ltd. (SWISS: BSLN) announces that the National Institute for Health and Clinical Excellence (NICE) issued the Final Appraisal Determination (FAD) recommending the use of Toctino® (alitretinoin) within its licensed indication, as a treatment option for adults with severe chronic hand eczema that has not responded to potent topical corticosteroids.
Oncology

AVI BioPharma, Inc. To Present At 7th Annual Biodefense Vaccines & Therapeutics Conference In Washington, D.C.

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, announced that Patrick Iversen, Ph.D., Senior Vice President of Strategic Alliances, will present at the upcoming 7th Annual Biodefense Vaccines & Therapeutics conference taking place in Washington, D.C. Dr. Iversen will present on Monday, June 15, as part of a pre-conference symposium on "Developments in Biodefense Technology Platform." He will be a featured speaker in a session titled "Building Technology Platforms to Array Against Multiple Threats," where he will discuss the utility of AVI"s RNA-based drugs against biological threats, including Ebola and Marburg viruses. AVI has begun to evaluate the rapid mobilization of RNA-based drugs against positive and negative strand RNA viruses. This analysis includes target optimization, avoidance of drug resistance and the relative advantages of virus-specific and host immune response-specific therapeutics to both improve host protection and reduce disease. Information about the conference can be found here. AVI BioPharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009